Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-6-3
pubmed:abstractText
To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1556-1380
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
631-6
pubmed:meshHeading
pubmed-meshheading:18520803-Adult, pubmed-meshheading:18520803-Aged, pubmed-meshheading:18520803-Aged, 80 and over, pubmed-meshheading:18520803-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:18520803-Disease Progression, pubmed-meshheading:18520803-Disease-Free Survival, pubmed-meshheading:18520803-Dose-Response Relationship, Drug, pubmed-meshheading:18520803-Female, pubmed-meshheading:18520803-Humans, pubmed-meshheading:18520803-Lung Neoplasms, pubmed-meshheading:18520803-Male, pubmed-meshheading:18520803-Middle Aged, pubmed-meshheading:18520803-Neoplasm Staging, pubmed-meshheading:18520803-Questionnaires, pubmed-meshheading:18520803-Severity of Illness Index, pubmed-meshheading:18520803-Sulfonamides, pubmed-meshheading:18520803-Survival Rate, pubmed-meshheading:18520803-Treatment Outcome, pubmed-meshheading:18520803-United States
pubmed:year
2008
pubmed:articleTitle
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
pubmed:affiliation
University of Chicago Medical Center, Chicago, Illinois 60637, USA. ann.mauer-md@advocatehealth.com
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II